THURSDAY, SEPTEMBER 21, 2017

Perlstein Lab raises $2 million towards production of treatments for rare conditions

San Francisco-based Perlstein Lab recently closed a $2 million seed round co-led by clinical-stage "orphan drug" developer Retrophin and the Wilsey family, which is personally affected by an "orphan disease." Read More »

ImmunoClin names Heinz Ellerbrok to Scientific Advisory Board

ImmunoClin Corp., a company specializing in personalized medicine, anti-inflammatory therapies and nutritional formulations, announced on Tuesday that Heinz Ellerbrok was appointed to its Scientific Advisory Board. Read More »

Arena Solutions integrates PLM applications with SiliconExpert's components database

Arena Solutions, the developer of cloud-based product lifecycle management (PLM) applications, announced on Tuesday that it has integrated the applications with SiliconExpert Technologies' electronic components information database. Read More »

Study finds herpes zoster vaccine effective after chemotherapy

A study published on Tuesday revealed that the herpes zoster vaccine continues to be effective in protecting older adults from shingles even after they undergo chemotherapy. Read More »

Orbactiv approved by FDA to treat serious bacterial skin infection in adults

The U.S. Food and Drug Administration approved a new antibiotic called Orbactiv (oritavancin) last week to treat adults with skin infection. Read More »

EMA accepts expanded Prevenar indication application

Pfizer, Inc., announced on Thursday that the European Medicines Agency (EMA) accepted the company's application to expand the indication of Prevenar 13 to include the prevention of pneumonia caused by the pneumococcal serotypes in the vaccine. Read More »

Niger launches nationwide dual child immunization campaign

Niger recently became the fourth country globally to launch a nationwide vaccination campaign in children against pneumonia and diarrhea-related viruses, which account for one in three deaths of children under the age of five in the country. Read More »

NFID announces three award recipients

The National Foundation for Infectious Diseases (NFID) announced the recipients on Thursday of three prestigious awards. Read More »

Urologist Frank Glover testifies on combating ebola

Ebola Read More »

Equatorial Guinea's president calls on American businesses to support efforts to end malaria

Equatorial Guinea President Obiang Nguema Mbasogo called on the American business community to ramp up cooperative efforts with African nations to combat malaria in the country. Read More »

Study finds master toxin regulator in staph infections

Staphylococcus aureus Read More »

TB vaccine may protect against progression to disease

Tuberculosis Read More »

Study finds new antimalarial treatment effective for children

Malaria Read More »

VGTI Florida seeks to stop chikungunya spread with new vaccine

chikungunya virus Read More »

Hajj pilgrims leaving from U.K. required to vaccinate against meningitis

The Meningitis Research Foundation recently urged Hajj pilgrims embarking on a trip to Mecca from the U.K. to ensure their vaccinations are up-to-date to meet visa requirements. Read More »

Save the Children to step up ebola response

Save the Children announced on Friday that it is rapidly scaling up its response to the ebola outbreak in West Africa. Read More »

WHO to convene ethical review of experimental treatment for Ebola

Ebola Read More »

WHO: Fear hinders efforts to contain Ebola outbreak in West Africa

The World Health Organization said on Monday a number of factors, such as a lack of space for infected patients, are hindering efforts to contain the spread of the Ebola virus in West Africa. Read More »

WHO panel deems use of experimental ebola treatments ethical

A panel of medical experts convened by the World Health Organization said on Monday that it is ethical to use experimental ebola virus treatments to combat the ongoing outbreak in West Africa. Read More »

Mississippi confirms first West Nile virus-related death

West Nile virus Read More »